Article
Endocrinology & Metabolism
J. Everts-Graber, S. Reichenbach, B. Gahl, H. R. Ziswiler, U. Studer, T. Lehmann
Summary: Patients who received zoledronate after denosumab discontinuation had fewer vertebral fractures, while all subsequent therapies were able to maintain bone mineral density to some extent. Factors such as age, BMI, treatment duration, prior therapy, and BMD gains during denosumab treatment influenced bone mineral density loss, while bone turnover markers correlated with total hip bone loss and treatment duration.
Article
Endocrinology & Metabolism
Tomaz Kocjan, Antonela Sabati Rajic, Andrej Janez, Gaj Vidmar, Nina Orehek, Janja Marc, Barbara Ostanek
Summary: This retrospective study compared bone mineral density changes in postmenopausal women with severe osteoporosis after stopping teriparatide therapy and receiving denosumab or bisphosphonates treatment for 12 months. The results showed that after 12 months, sequential denosumab treatment appeared to yield higher additional lumbar spine bone mineral density gain compared with bisphosphonates treatment.
ENDOCRINE PRACTICE
(2021)
Article
Endocrinology & Metabolism
Nicholas R. Fuggle, Beth Curtis, Michael Clynes, Jean Zhang, Kate Ward, Muhammad Kassim Javaid, Nicholas C. Harvey, Elaine Dennison, Cyrus Cooper
Summary: Despite significant progress in understanding osteoporosis over the past three decades, there is still a treatment gap where many high-risk individuals go untreated. This review highlights the patient, physician, and policy-related factors contributing to this gap, and focuses on discussing the efficacy and adverse effects of bisphosphonates in osteoporosis treatment, as well as strategies to improve prevention pathways for the disorder.
Review
Medicine, General & Internal
SeokJoon Hwang, Minsu Seo, Dongin Lim, Min Suk Choi, Jin-Woo Park, Kiyeun Nam
Summary: This literature review investigated the characteristics and management of bisphosphonate-associated bilateral atypical femoral fractures (AFFs). A comprehensive analysis of 43 patients with bilateral AFFs revealed that 67% had prodromal symptoms, 49% occurred simultaneously, and 51% occurred sequentially. X-ray was used for initial diagnosis, with 53% having complete fractures. Surgical treatment was performed for all patients, except for those with incomplete fractures who received either surgical or medical treatments. Teriparatide was the most commonly used medication after bisphosphonate discontinuation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Endocrinology & Metabolism
Elena Tsourdi, M. Carola Zillikens, Christian Meier, Jean-Jacques Body, Elena Gonzalez Rodriguez, Athanasios D. Anastasilakis, Bo Abrahamsen, Eugene McCloskey, Lorenz C. Hofbauer, Nuria Guanabens, Barbara Obermayer-Pietsch, Stuart H. Ralston, Richard Eastell, Jessica Pepe, Andrea Palermo, Bente Langdahl
Summary: Discontinuation of denosumab results in increased bone turnover, rapid bone loss, and risk of multiple vertebral fractures in some patients. Prior bisphosphonate therapy or subsequent antiresorptive treatment may help mitigate the biochemical rebound phenomenon after denosumab discontinuation.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Marianne Lamarre, Martine Marcotte, Danielle Laurin, Daniela Furrer, Isabelle Vedel, Andre Tourigny, Anik Giguere, Pierre-Hugues Carmichael, Rosa Martines, Jose Morais, Edeltraut Kroger
Summary: Bisphosphonates can be successfully discontinued after at least 3 years of use, with low overall fracture risk. However, there is a risk for decreased BMD and increased vertebral fractures upon discontinuation according to some studies.
ARCHIVES OF OSTEOPOROSIS
(2021)
Article
Health Care Sciences & Services
Sara Jane Cromer, Kristin M. D'Silva, Elaine W. Yu, Joan Landon, Rishi J. Desai, Seoyoung C. Kim
Summary: The study found that the use of denosumab has surpassed all other bone-directed therapies over the past decade, especially since its approval in 2010. The use of denosumab also showed increasing trends among patients with osteoporosis, malignancies, and recent fractures. However, it is noteworthy that the proportion of using any bone-directed therapy after fractures is low and has declined over time.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Teerapat Tutaworn, Jeri W. Nieves, Zhaorui Wang, Justin E. Levin, Jae E. Yoo, Joseph M. Lane
Summary: A retrospective study found that treatment with ALN or ZOL can mitigate BMD loss after Dmab discontinuation, while NT and RIS treatment cannot.
OSTEOPOROSIS INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Toshihiro Nanki, Mai Kawazoe, Kiyoko Uno, Wataru Hirose, Hiroaki Dobashi, Hiroshi Kataoka, Toshihide Mimura, Hiroshi Hagino, Hajime Kono
Summary: This study assessed the effect of switching to weekly teriparatide on glucocorticoid-induced osteoporosis patients. The results showed that switching to once-weekly teriparatide can increase bone mineral density and reduce the occurrence of new fractures.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Endocrinology & Metabolism
Ian R. Reid, Anne M. Horne, Borislav Mihov, Sonja Bastin, Gregory D. Gamble
Summary: Bisphosphonates are commonly used for osteoporosis prevention and treatment, while NSAIDs are widely used by older adults at high fracture risk. A study reanalyzed data from a clinical trial of zoledronate and found that NSAID use did not affect the bone density or fracture risk reduction effects of zoledronate. The study concluded that NSAIDs do not interfere with the efficacy of potent bisphosphonates in terms of bone density or fracture.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Gregory A. A. Kline, Suzanne N. N. Morin, Lisa M. M. Lix, William D. D. Leslie
Summary: Based on the FLEX study in 2006, a 5-year course of bisphosphonate therapy was found to be sufficient for most women. However, despite the increased risk of atypical femoral fractures associated with long-term use, up to one-third of patients continued to receive bisphosphonate therapy for over 10 years after 2010.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Orthopedics
Di-chen Zhao, Xiao-yun Lin, Jing Hu, Bing-na Zhou, Qian Zhang, Ou Wang, Yan Jiang, Wei-bo Xia, Xiao-ping Xing, Mei Li
Summary: Men with osteoporosis have significantly impaired health-related quality of life, and the severity of osteoporosis is negatively correlated with quality of life. Fragility fracture is an important factor contributing to decreased quality of life. Treatment with bisphosphonates can improve the health-related quality of life in men with osteopenia/osteoporosis.
BMC MUSCULOSKELETAL DISORDERS
(2023)
Review
Medicine, General & Internal
Kaleen N. Hayes, Elizabeth M. Winter, Suzanne M. Cadarette, Andrea M. Burden
Summary: Bisphosphonates are the primary treatment for osteoporosis, and a drug holiday of two to three years is recommended for most patients after long-term use to reduce the risk of adverse events. Duration of bisphosphonate effects during the drug holiday and individual patient factors should be considered when determining the appropriate time to stop therapy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Gregory A. Kline, Suzanne N. Morin, Lisa M. Lix, William D. Leslie
Summary: Bone mineral density (BMD) loss shows greater variability at shorter testing intervals, but this variability diminishes over longer intervals. Using reports of rapid BMD loss as an indication for antifracture medication initiation may not be accurate.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Geriatrics & Gerontology
Nicholas Fuggle, Nasser Al-Daghri, Olivier Bock, Jaime Branco, Olivier Bruyere, Enrique Casado, Etienne Cavalier, Bernard Cortet, Maarten de Wit, Andrea Giusti, Philippe Halbout, Nicholas C. Harvey, Mickael Hiligsmann, Jean-Marc Kaufman, Andreas Kurth, Stefania Maggi, Radmila Matijevic, Salvatore Minisola, Santiago Palacios, Regis Pierre Radermecker, Friederike Thomasius, Sansin Tuzun, Nicola Veronese, John A. Kanis, Jean-Yves Reginster, Rene Rizzoli, Cyrus Cooper
Summary: Oral bisphosphonates are important in the treatment of osteoporosis, but poor adherence is a problem. New formulations aim to improve tolerance and adherence, potentially leading to better fracture outcomes.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Health Care Sciences & Services
Joanna L. Whyte, Nicole M. Engel-Nitz, April Teitelbaum, Gabriel Gomez Rey, Joel D. Kallich
Article
Pharmacology & Pharmacy
Xue Song, Stacey R. Long, William D. Marder, Sean D. Sullivan, Joel Kallich
ANNALS OF PHARMACOTHERAPY
(2009)
Correction
Endocrinology & Metabolism
Xue Song, Nianwen Shi, Enkhe Badamgarav, Joel Kallich, Helen Varker, Gregory Lenhart, Jeffrey R. Curtis
Article
Endocrinology & Metabolism
Xue Song, Nianwen Shi, Enkhe Badamgarav, Joel Kallich, Helen Varker, Gregory Lenhart, Jeffery R. Curtis
Article
Endocrinology & Metabolism
Sally W. Wade, Jeffrey R. Curtis, Jingbo Yu, Jeffrey White, Bradley S. Stolshek, Claire Merinar, Akhila Balasubramanian, Joel D. Kallich, John L. Adams, Hema N. Viswanathan
Article
Endocrinology & Metabolism
Jeffrey R. Curtis, Qian Cai, Sally W. Wade, Bradley S. Stolshek, John L. Adams, Akhila Balasubramanian, Hema N. Viswanathan, Joel D. Kallich
Article
Oncology
David Cella, Hema N. Viswanathan, Ron D. Hays, Tito R. Mendoza, Kevin D. Stein, David J. Pasta, Aimee J. Foreman, Saroj Vadhan-Raj, Joel D. Kallich
Article
Pharmacology & Pharmacy
Arlel Berger, John Edelsberg, Joel Kallich, Gerry Oster
CLINICAL THERAPEUTICS
(2008)
Article
Medicine, General & Internal
Gregory Daniel, Dana Hurley, Joanna L. Whyte, Vincent Willey, Marcus Wilson, Joel Kallich
CURRENT MEDICAL RESEARCH AND OPINION
(2009)
Article
Endocrinology & Metabolism
M. A. Ward, Y. Xu, H. N. Viswanathan, B. S. Stolshek, B. Clay, J. L. Adams, J. D. Kallich, S. Fine, K. G. Saag
OSTEOPOROSIS INTERNATIONAL
(2013)
Article
Economics
Daniel Polsky, Daria Eremina, Gregory Hess, Jerrold Hill, Scott Hulnick, Adam Roumm, Joanna L. Whyte, Joel Kallich
Article
Public, Environmental & Occupational Health
Beth L. Nordstrom, Joanna L. Whyte, Marilyn Stolar, Catherine Mercaldi, Joel D. Kallich
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2012)
Article
Oncology
Benjamin Chastek, Carolyn Harley, Joel Kallich, Lee Newcomer, Carly J. Paoli, April H. Teitelbaum
JOURNAL OF ONCOLOGY PRACTICE
(2012)
Article
Economics
Hema N. Viswanathan, Jeffrey R. Curtis, Jingbo Yu, Jeffrey White, Bradley S. Stolshek, Claire Merinar, Akhila Balasubramanian, Joel D. Kallich, John L. Adams, Sally W. Wade
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
(2012)